Litigation Details for Bayer Intellectual Property GmbH v. Micro Labs Ltd. (D. Del. 2017)

« Back to Dashboard

Bayer Intellectual Property GmbH v. Micro Labs Ltd. (D. Del. 2017)

Docket	1:17-cv-00560	Date Filed	2017-05-12
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,539,218
Link to Docket	External link to docket

Details for Bayer Intellectual Property GmbH v. Micro Labs Ltd. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-05-12	1		FDA. 22. U.S. Patent No. 9,539,218 (“the ’218 patent”), entitled “Prevention and Treatment…products prior to the expiration of U.S. Patent No. 9,539,218. Case 1:17-cv-00560-UNA Document 1 Filed… 1. This is an action for patent infringement under the patent laws of the United States, Title…forth in greater detail in the ’218 patent, the claims of the ’218 patent, incorporated by reference herein…the ’218 patent. 25. Bayer AG is an exclusive licensee under the ’218 patent.	External link to document
2017-05-12	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,539,218 B2. (crb) (Entered:… 12 May 2017 1:17-cv-00560 830 Patent None District Court, D. Delaware	External link to document
2017-05-12	9		23 PageID #: 39 United States Patent No. 9,539,218 (“the ‘218 patent”). Micro Labs admits that Micro…Paragraph 21. 22. U.S. Patent No. 9,539,218 (“the ‘218 patent”), entitled “Prevention and Treatment…or more claims of United States Patent No. 9,539,218 (“the ‘218 patent”) 3. Micro Labs USA…products prior to the expiration of U.S. Patent No. 9,539,218. ANSWER: Paragraph 1 contains… 1. This is an action for patent infringement under the patent laws of the United States, Title	External link to document

Bayer Intellectual Property GmbH v. Micro Labs Ltd. Litigation Summary and Patent Analysis

Last updated: September 5, 2026

Bayer Intellectual Property GmbH v. Micro Labs Ltd., No. 1:17-cv-00560-RGA, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Micro Labs' proposed generic version of Xarelto, the rivaroxaban anticoagulant marketed by Bayer and Janssen. Bayer filed the action after receiving a Paragraph IV certification to patents covering rivaroxaban and its pharmaceutical formulations. The case ended without a reported trial or merits decision after the parties entered into a confidential settlement and stipulated to dismissal. The public docket does not disclose the settlement's launch date, royalty terms, or other commercial conditions. (Bayer Intellectual Property GmbH v. Micro Labs Ltd., No. 1:17-cv-00560-RGA, D. Del.)

What drug and regulatory filing were involved in the Bayer v. Micro Labs case?

The dispute involved rivaroxaban, the active ingredient in Xarelto tablets. Xarelto is an orally administered direct factor Xa inhibitor used to reduce thromboembolic risk in several cardiovascular and orthopedic settings.

Item	Detail
Brand	Xarelto
Active ingredient	Rivaroxaban
Sponsor	Janssen Pharmaceuticals, Inc., with Bayer affiliates
NDA	NDA 022406
FDA approval	2011
Dosage forms	Immediate-release tablets; later oral suspension and additional strengths
Regulatory pathway	ANDA Paragraph IV patent challenge
Defendant	Micro Labs Ltd.
Case number	1:17-cv-00560-RGA
Court	U.S. District Court for the District of Delaware
Filing year	2017

Micro Labs' ANDA sought approval for generic rivaroxaban tablets. The filing triggered the statutory 30-month stay under the Hatch-Waxman Act, subject to termination or modification by court order or other statutory events. The case was one of several patent actions filed by Bayer against generic manufacturers seeking approval for rivaroxaban products.

What patents did Bayer assert against Micro Labs?

Bayer's complaint alleged infringement of Orange Book-listed patents covering rivaroxaban and pharmaceutical compositions containing the drug. The asserted patent set in Xarelto litigation generally included the following patents:

Patent	Subject matter	Relevance to Xarelto
U.S. Patent No. 7,157,456	Rivaroxaban compound and therapeutic use	Core active-ingredient patent
U.S. Patent No. 8,669,373	Pharmaceutical formulation containing rivaroxaban	Formulation protection
U.S. Patent No. 9,539,218	Rivaroxaban pharmaceutical composition and related formulation claims	Later-expiring formulation protection

The patent claims at issue depended on the precise contents of Micro Labs' ANDA and the scope of the Paragraph IV certifications. Hatch-Waxman complaints commonly plead infringement under 35 U.S.C. § 271(e)(2), which treats submission of an ANDA seeking approval before patent expiration as an artificial act of infringement for purposes of resolving patent rights before generic launch.

The public record does not establish a final claim-construction ruling, invalidity decision, or infringement judgment in the Micro Labs action. The case therefore does not provide a judicial determination that the asserted patents were valid, enforceable, and infringed by Micro Labs.

When do the Xarelto patents lose exclusivity?

The core compound patent and later formulation patents had different expiration profiles. Patent expiration dates can vary based on patent-term adjustment, terminal disclaimers, pediatric exclusivity, and the specific Orange Book listing.

Patent	General protection category	Publicly reported expiration period
U.S. 7,157,456	Rivaroxaban compound and use	December 2024, before applicable pediatric extension
U.S. 8,669,373	Rivaroxaban formulation	2026 period
U.S. 9,539,218	Later formulation protection	2027 period

FDA approval exclusivity and patent exclusivity are separate. Xarelto's original new chemical entity exclusivity expired years before the relevant patent estate. The commercial barrier after regulatory exclusivity was therefore primarily patent-based.

The most important business distinction is between compound protection and formulation protection. Once the compound patent expires, an ANDA applicant may still face infringement risk if its proposed dosage form practices valid formulation claims. A generic applicant can attempt to avoid those claims through a non-infringing formulation, challenge validity, or negotiate a licensed entry date.

What was Micro Labs' Paragraph IV challenge?

Micro Labs' ANDA certification asserted that the relevant Xarelto patents were invalid, unenforceable, or would not be infringed by the proposed generic product. A Paragraph IV certification is a statutory challenge under 21 U.S.C. § 355(j)(2)(A)(vii)(IV). It permits the ANDA applicant to seek approval before expiration of the listed patents, while exposing the applicant to patent litigation.

Bayer's complaint converted the certification into a patent case under § 271(e)(2). The litigation would have addressed:

• Whether Micro Labs' proposed rivaroxaban product fell within the asserted claims.
• Whether the asserted claims were anticipated or obvious.
• Whether formulation claims were adequately supported and enabled.
• Whether Bayer's patents were enforceable.
• Whether the statutory 30-month stay should delay FDA approval.

Because the case settled, none of these questions received a final merits ruling in this docket.

How did the Bayer v. Micro Labs litigation end?

The action ended through a settlement-related dismissal rather than a reported judgment after trial. The public docket does not disclose the settlement agreement's terms.

The available record supports the following conclusions:

1. Bayer did not obtain a publicly reported infringement judgment against Micro Labs.
2. Micro Labs did not obtain a publicly reported invalidity judgment against Bayer.
3. The court did not issue a published claim-construction opinion resolving the principal patent disputes.
4. The settlement likely resolved Micro Labs' U.S. launch risk, but the public docket does not state the authorized launch date.
5. The dismissal did not eliminate the underlying patents or determine their validity against other generic manufacturers.

A confidential settlement can preserve substantial patent value even when no merits ruling is issued. It can also provide the generic manufacturer with a defined launch path, subject to the patent estate, regulatory approval, manufacturing readiness, and any settlement restrictions.

What was the Orange Book status of Xarelto?

Xarelto's Orange Book status reflected FDA-listed patents for the approved rivaroxaban products. Orange Book listings give ANDA applicants notice of patents that the NDA holder identifies as claiming the drug or an approved method of using it. They do not independently establish patent validity or infringement.

The listed patents created several potential litigation layers:

Compound patents

Compound claims provide the broadest protection because they cover the active pharmaceutical ingredient itself. A generic applicant generally cannot market rivaroxaban without confronting the compound patent unless the patent has expired, is successfully challenged, or the product is licensed for launch.

Formulation patents

Formulation claims can cover dosage forms, excipients, dissolution characteristics, particle properties, or other product architecture. These claims are narrower than compound claims but can extend effective protection after compound-patent expiration.

Method-of-use patents

Method-of-use listings can cover particular dosing regimens or indications. A generic applicant may use a section viii statement to carve out a patented indication if the proposed label can omit that use. Carve-outs are more difficult when the patented use is embedded in the principal approved indication or when doctors are expected to prescribe the generic for the protected use.

How strong was Bayer's patent estate against Micro Labs?

Bayer's position was stronger than a single-patent case because the Xarelto estate combined compound and formulation protection. That structure created several litigation and launch barriers:

Risk factor	Effect on Micro Labs
Compound patent	Direct challenge to the active ingredient
Formulation patents	Potential infringement despite compound-patent expiry
Multiple listed patents	More opportunities for Bayer to delay or condition entry
ANDA filing	Triggered a statutory infringement action
Confidential settlement	Removed the need for Micro Labs to litigate through judgment
Competing generic cases	Increased the value of coordinated settlement strategy

The estate's practical strength depended on claim scope and validity, not merely on the number of patents. Formulation patents generally present more design-around opportunities than compound patents. A generic manufacturer may alter excipients, particle size, manufacturing conditions, or dissolution properties, but those changes can affect bioequivalence and commercial scalability.

What generic entry risks existed for Micro Labs?

Micro Labs faced five principal risks:

1. An adverse infringement judgment could have delayed approval until the latest enforceable patent expiration.
2. An invalidity challenge could have failed if Bayer established non-obviousness, adequate written description, enablement, and claim scope.
3. A formulation design-around could have required additional development and FDA review.
4. A settlement could have restricted launch timing or imposed financial obligations.
5. Even after patent clearance, commercial entry would have depended on FDA approval, manufacturing capacity, pricing, and competition from other generic applicants.

The settlement reduced litigation uncertainty but did not guarantee commercial success. Several approved or pending generic manufacturers could enter the market around the same time, producing rapid price erosion.

Did the case create biosimilar risk?

No. Rivaroxaban is a synthetic small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA for a generic drug under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k) of the Public Health Service Act.

The appropriate competitive risks were generic substitution, Paragraph IV litigation, formulation design-arounds, and authorized or licensed generic entry. Biosimilar interchangeability standards were not relevant to this case.

Which companies challenged Xarelto patents?

Bayer filed parallel Xarelto patent litigation against multiple generic manufacturers, including companies such as Teva, Mylan, Lupin, Hetero, Aurobindo, and other ANDA applicants. The exact asserted patent combinations and procedural outcomes varied by defendant.

Parallel litigation increased pressure on Bayer because an invalidity or non-infringement ruling in one case could affect settlement leverage in others. It also increased pressure on generic companies because early settlements could define launch economics and market-entry timing.

What revenue exposure did the litigation create?

Xarelto was one of Bayer's largest pharmaceutical products. Bayer reported multi-billion-dollar annual global sales for Xarelto in the years surrounding the litigation. U.S. generic entry threatened:

• Loss of branded tablet volume.
• Price reductions caused by automatic substitution.
• Rebates and formulary pressure before generic launch.
• Reduced value of later patent and formulation rights.
• Revenue sharing implications under the Bayer-Janssen commercial arrangement.

The commercial impact depended on whether entry occurred before or after the final formulation patent expiration, how many generic suppliers launched, and whether an authorized generic was introduced.

What is the current litigation status?

Bayer Intellectual Property GmbH v. Micro Labs Ltd., No. 1:17-cv-00560-RGA, is closed. The case did not produce a publicly reported merits decision. Its principal continuing significance is commercial rather than precedential: it illustrates how Bayer used a layered rivaroxaban patent estate to negotiate with ANDA applicants before generic entry.

Key Takeaways

• The case involved Micro Labs' ANDA for generic rivaroxaban, the active ingredient in Xarelto.
• Bayer asserted Orange Book-listed compound and formulation patents.
• The action was filed in the District of Delaware in 2017 under the Hatch-Waxman framework.
• The case ended in a settlement-related dismissal without a reported trial or merits judgment.
• Public filings do not disclose the settlement's launch date or financial terms.
• Xarelto's commercial protection extended beyond the compound patent through later formulation patents.
• Biosimilar law was not relevant because rivaroxaban is a small-molecule drug.
• The principal post-litigation risk was generic entry after the applicable patent barriers and any settlement restrictions expired.

FAQs About Bayer v. Micro Labs and Xarelto Patent Litigation

Was Bayer v. Micro Labs a patent infringement case?

Yes. It was a Hatch-Waxman action alleging that Micro Labs' ANDA submission infringed Bayer's rivaroxaban patents under 35 U.S.C. § 271(e)(2).

Did Micro Labs win the patent challenge?

No merits victory is publicly reported. The case ended through settlement-related dismissal, so the court did not issue a public invalidity or non-infringement judgment.

Did the settlement allow Micro Labs to launch generic Xarelto?

The settlement presumably resolved Micro Labs' launch restrictions, but the public docket does not disclose whether or when Micro Labs received a licensed launch date.

Are Xarelto patents still relevant after the 2024 compound-patent expiration?

Yes. Later formulation patents and any applicable patent-term adjustments or regulatory exclusivities can remain relevant after expiration of the core compound patent.

Is generic rivaroxaban subject to biosimilar approval rules?

No. Generic rivaroxaban is approved through the ANDA pathway because rivaroxaban is a synthetic small-molecule active ingredient.

References

1. Bayer Intellectual Property GmbH v. Micro Labs Ltd., No. 1:17-cv-00560-RGA, U.S. District Court for the District of Delaware, docket and pleadings.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2011). Xarelto (rivaroxaban) NDA 022406 approval letter and prescribing information.

4. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,157,456: Oxazolidinones and their use in the treatment of thromboembolic disorders.

5. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,669,373.

6. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,539,218.

7. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

8. Patent Act, 35 U.S.C. § 271(e)(2).